Kisspeptin side effects by evidence tier: what several hundred volunteers in the human physiology and IVF studies showed, the predictable endocrine effects, tachyphylaxis, and the gaps.
Kisspeptin is unusual among research peptides in having a real human safety record: the KISS1 neuropeptide has been given to several hundred volunteers and patients, mostly in physiology studies from Imperial College London, since 2005. That record is also narrow — short exposures, clinical-grade preparations, hospital monitoring, and mostly the 54-residue form rather than the kisspeptin-10 sold for research. This page separates what those studies reported from what they never tested, and sits beside the Kisspeptin profile as a research reference rather than advice.
Almost all research-grade kisspeptin is kisspeptin-10, the C-terminal ten residues of the KISS1 precursor. Almost all of the human tolerability data comes from kisspeptin-54, the full-length peptide used in the IVF trigger trials and most of the subcutaneous physiology work. The two act on the same receptor with the same potency, but their half-lives differ sevenfold — about 28 minutes against about 4 minutes — and the only human kisspeptin-10 studies on file used intravenous boluses and infusions in a research unit. Carrying kisspeptin-54 tolerability numbers across to subcutaneous kisspeptin-10 is an inference, not a finding. The kisspeptin research overview covers the pharmacology behind that gap.
Healthy volunteers. Dhillo and colleagues (Journal of Clinical Endocrinology & Metabolism, 2005) infused kisspeptin-54 intravenously in men; the 2011 JCEM study gave kisspeptin-10 intravenously to men as boluses of 0.3 to 1 µg/kg and infusions of 4 µg/kg/h; and later work gave subcutaneous kisspeptin-54 to women across the menstrual cycle. Across this body of work the profile's summary is consistent: no serious adverse events attributed to the peptide, occasional mild injection-site reactions with subcutaneous kisspeptin-54, and no consistent effects on heart rate or blood pressure at the doses studied.
IVF triggering. Jayasena and colleagues (Journal of Clinical Investigation, 2014) gave a single subcutaneous kisspeptin-54 injection of 1.6 to 12.8 nmol/kg as the oocyte-maturation trigger; oocyte maturation occurred in nearly all women and live births followed. The 2015 study (Abbara et al., JCEM) used 9.6 nmol/kg in women at high risk of ovarian hyperstimulation syndrome and reported no cases of severe OHSS. That result was the safety rationale for the whole programme: kisspeptin produces an endogenous, self-limiting LH surge, whereas the standard hCG trigger stimulates the ovary for days and is the principal cause of OHSS.
Hypothalamic amenorrhoea. Jayasena et al. (JCEM, 2009) gave subcutaneous kisspeptin-54 at 6.4 nmol/kg twice daily to women with hypothalamic amenorrhoea. Tolerability was not the finding; the finding was that the gonadotropin response faded within two weeks. That is discussed below as an effect in its own right.
Kisspeptin's safety signals are the consequences of what it does. It raises LH, FSH and sex steroids within minutes, so in men a rise in testosterone and oestradiol follows, and in women cycle timing shifts, with the size of the LH response depending on cycle phase. Any consequence of those hormones follows from them.
The second signal runs the other way. Continuous or frequent exposure desensitises the axis — the tachyphylaxis demonstrated within two weeks of twice-daily dosing in 2009 — and lowers gonadotropins, the reverse of the acute effect. It is the same desensitisation that GnRH agonists produce, and no study has characterised how long recovery takes after longer courses.
The published record supports a narrow claim — kisspeptin-54 and intravenous kisspeptin-10 were well tolerated in short, monitored exposures — and nothing broader. There is no controlled human safety data for:
The biology outside the reproductive axis is also incompletely mapped. KISS1 was discovered as a metastasis suppressor and KISS1R is expressed in several tissues; animal work links kisspeptin to glucose handling and to a liver-derived kisspeptin that suppresses insulin secretion. Nothing in the human record addresses those systems, and the long-term consequences of exogenous kisspeptin in people are unknown. "Not looked for" and "looked for and not found" are different statements, and only the first applies here.
Community and vendor reporting on kisspeptin-10 is sparse, uncontrolled, unblinded and without a denominator. It cannot establish incidence, causation or severity, and it comes from a form and route the clinical studies did not use. Treat such reports as hypotheses, not findings.
Some share of any reaction to unregulated peptide material plausibly traces to the vial rather than the molecule. Kisspeptin-10 contains a tryptophan and a tyrosine, both susceptible to oxidation, and it is light-sensitive; degraded material, synthesis impurities, residual trifluoroacetate from the salt form, or endotoxin load would all be invisible without analysis. Third-party HPLC purity and mass-spectrometry identity are the only way to separate compound effects from product effects — see lab testing and COAs and the cold-chain and shelf-life guide. Research-grade kisspeptin-10 is sold here as a lyophilised vial with a certificate of analysis available on request.
Kisspeptin has no Health Canada market authorisation in any form and no DIN. It is not a controlled substance, and research-grade kisspeptin-10 is sold in Canada strictly for laboratory research. In the United States, the FDA placed kisspeptin-10 in category 2 of its September 2023 evaluation of bulk substances for section 503A compounding, so it may not be used in compounded medicines there. On anti-doping, the WADA Prohibited List places LH-releasing factors under S2 as prohibited in males, and kisspeptin and its agonist analogues are named in that group; tested athletes should verify the wording of the list in force.
Does kisspeptin have a documented side-effect profile? A narrow one. Across several hundred volunteers and patients, clinical-grade kisspeptin-54 and intravenous kisspeptin-10 produced no serious adverse events attributed to the peptide, occasional mild injection-site reactions, and no consistent cardiovascular effects. Subcutaneous kisspeptin-10, the research-grade form and route, has no controlled human safety data.
What did the IVF studies report about ovarian hyperstimulation? The 2015 study in women at high risk of OHSS, using a single 9.6 nmol/kg subcutaneous kisspeptin-54 trigger, reported no cases of severe OHSS. That reflects kisspeptin's short, self-limiting LH surge compared with the days-long ovarian stimulation of an hCG trigger, in a monitored IVF setting.
What is the tachyphylaxis effect? Twice-daily subcutaneous kisspeptin-54 in women with hypothalamic amenorrhoea lost its gonadotropin-stimulating effect within two weeks (Jayasena 2009). Frequent exposure desensitises the axis and lowers gonadotropins — the reverse of a single dose — which is why later designs spaced injections apart.
Is kisspeptin prohibited in sport? Yes for male athletes: WADA lists LH-releasing factors, kisspeptin and its agonist analogues among them, under S2 as prohibited in males. Athletes should check the current List directly.
Is this medical advice? No. Kisspeptin-10 sold here is research-grade material for laboratory use only, not for human or veterinary use. This page reports what published studies observed; it is not a safety assurance, a dosing recommendation or medical advice, and the absence of reported effects is not evidence of safety.
